# Novartis's $2B Deal Targets the Tolerability Problem That Limits Every PI3K Cancer Drug - Date: 2026-03-20 - Category: Biotech & Life Sciences Novartis is acquiring a PI3Kα inhibitor from Synnovation Therapeutics that is designed to spare normal cells — addressing the tolerability problem that has limited this drug class in solid tumors. ---